Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 15/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4107928 | 0.88 | SCN9A (0.54) | BCHENPC1KDM4EL3MBTL1 | |
| SCHEMBL8964423 | 0.83 | BCHE (0.68) | BCHEKDM4EL3MBTL1 | |
| SCHEMBL5511945 | 0.80 | PTPRC (0.54) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL4101732 | 0.77 | ABCB1 (0.56) | BCHESMN1; SMN2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL30889094 | 0.77 | APP (0.63) | NPC1ALDH1A1KDM4E | |
| SCHEMBL4103211 | 0.77 | BCHE (0.39) | BCHENPC1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL21030092 | 0.75 | ABCB1 (0.55) | TSHRSMN1; SMN2KDM4ENFE2L2 | |
| SCHEMBL5514300 | 0.74 | PPARD (0.46) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL12432418 | 0.73 | ADCYAP1R1 (0.47) | — | |
| SCHEMBL2500056 | 0.73 | SMN1; SMN2 (0.50) | TSHRSMN1; SMN2ALDH1A1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221829-A1 | 3,4-Dihydroisoquinolinium Salt Derivatives | HANWHA CHEMICAL CORPORATION (KR) | 2009-09-03 | — | — | US | disclosed |
| CN-101208305-A | 3,4-dihydroisoquinolinium salt derivatives | HANWHA CHEMICAL CORP (KR) | 2008-06-25 | — | — | CN | disclosed |
| EP-1896419-A1 | 3,4-DIHYDROISOQUINOLINIUM SALT DERIVATIVES | HANWHA CHEMICAL CORPORATION (KR) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006129978-A1 | 3,4-DIHYDROISOQUINOLINIUM SALT DERIVATIVES | HANWHA CHEMICAL CORPORATION (KR) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221829-A1 | 3,4-Dihydroisoquinolinium Salt Derivatives | KCNQ3, KCNQ1, KCNQ2 | BCHE 1438/4885NPC1 903/4885TSHR 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.